US FDA's Acting Orphan Products Development Director Has Gene Therapy Background
Ilan Irony will take over as acting director of the Office of Orphan Products Development later this month.
You may also be interested in...
The move means Hylton Joffe can focus exclusively on his role as director of the Office of Rare Diseases.
Janet Maynard will become acting Office of Orphan Products Development director at the end of October, the fourth head of the office in the last 10 months; staff is expected to grow and may begin to provide development advice.
Senior Biomedical Research Service expansion, used to attract elite scientists to federal service, may not be implemented until late 2019; FDA also may have a candidate for OND director.